Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Core Insights - Tevogen Bio Holdings Inc. has announced the potential value and forecast for its pipeline product, TVGN 930, aimed at treating non-solid tumor malignancies associated with Epstein-Barr Virus (EBV) [1][2] Financial Projections - The cumulative 5-year top-line revenue forecast for TVGN 930 is approximately $3.5 billion, reflecting the company's innovative drug development model [2] - The risk-adjusted Net Present Value (rNPV) for TVGN 930 is projected to exceed $250 million in the US alone [7] Market Opportunity - There are currently no approved vaccines for EBV, creating a significant therapeutic gap that TVGN 930 aims to fill [4] - The accessible market in the US for TVGN 930 could potentially cover up to 40,000 patients across five rare disease indications [7] Additional Applications - The treatment of multiple sclerosis through tighter EBV control presents an additional opportunity for the product [3]